Key Points
- Priapism from phosphodiesterase type 5 inhibitors (PDE5is) is only
recorded by limited case reports. This study sought to verify the low
incidence of priapism among PDE5i users in a large international
dataset and to assess the differences between different PDE5i products
in the development of priapism.
- We found a very small risk of priapism with PDE5is compared with other
adverse drug reactions.
- The use of PDE5is among young patients is associated with a higher
risk of priapism compared to adults, albeit low. Our analysis further
confirms that the risk of priapism amongst older men with erectile
dysfunction is extremely rare.